• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Medical Officer Albertson Tina M. was granted 14,589 shares (SEC Form 4)

    2/21/25 8:20:34 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRBU alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Albertson Tina M.

    (Last) (First) (Middle)
    C/O CARIBOU BIOSCIENCES, INC.
    2929 7TH STREET, SUITE 105

    (Street)
    BERKELEY CA 94710

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Caribou Biosciences, Inc. [ CRBU ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Medical Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    02/20/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 02/20/2025 A 14,589(1) A $0 14,589 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Option to purchase Common Stock $1.41 02/20/2025 A 66,137 (2) 02/19/2035 Common Stock 66,137 $0 66,137 D
    Explanation of Responses:
    1. This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2026, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date.
    2. 25% of the options will vest upon the one-year anniversary of the grant date, February 20, 2026, and 1/48th will vest monthly thereafter over the 36-month period following the one-year cliff, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.
    Remarks:
    /s/ Barbara G. McClung, as attorney-in-fact 02/21/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CRBU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRBU

    DatePrice TargetRatingAnalyst
    6/3/2024$13.00 → $3.00Outperform → In-line
    Evercore ISI
    11/8/2023Neutral
    Cantor Fitzgerald
    10/31/2023$13.00Outperform
    Evercore ISI
    7/11/2023$23.00Buy
    Truist
    2/18/2022$22.00Outperform
    RBC Capital
    2/14/2022$19.00Buy
    Brookline Capital
    12/1/2021$36.00Outperform
    Oppenheimer
    11/30/2021$28.00Buy
    H.C. Wainwright
    More analyst ratings

    $CRBU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference

      BERKELEY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4th at 9:20 AM EDT. For more information and a link to the webcast, visit the Events page on Caribou's website. Webcasts will be available on the Caribou website for at least 30 days after the event. About Caribou Biosciences, Inc.Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transforma

      5/28/25 4:00:00 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update

      -- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $212.5 million in cash, cash equivalents, and marketable securities expected to fund the Company's current operating plan into H2 2027 -- BERKELEY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the first quarter 2025 and provided a business update for its lead oncology clinical programs CB-010 and CB-011 with data disclosure for each planned for H2 2025. "Caribou's two lead Phase 1 clinical programs, CB-010 for large B cell lymphoma and CB-011 for

      5/8/25 4:05:00 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

      BERKELEY, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on May 13th at 2:35 PM PDT. For more information and a link to the webcast, visit the Events page on Caribou's website. Webcasts will be available on the Caribou website for at least 30 days after the event. About Caribou Biosciences, Inc.Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing trans

      5/6/25 4:00:00 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRBU
    SEC Filings

    See more
    • Caribou Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Caribou Biosciences, Inc. (0001619856) (Filer)

      6/13/25 4:02:09 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Caribou Biosciences Inc.

      EFFECT - Caribou Biosciences, Inc. (0001619856) (Filer)

      5/15/25 12:15:15 AM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Caribou Biosciences Inc.

      DEFA14A - Caribou Biosciences, Inc. (0001619856) (Filer)

      5/8/25 5:05:27 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRBU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Caribou Biosciences Inc.

      SC 13D/A - Caribou Biosciences, Inc. (0001619856) (Subject)

      12/6/24 4:06:56 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Caribou Biosciences Inc.

      SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)

      11/14/24 7:53:54 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Caribou Biosciences Inc.

      SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)

      11/14/24 6:08:51 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRBU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Haurwitz Rachel E. bought $20,400 worth of shares (20,000 units at $1.02) (SEC Form 4)

      4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

      3/17/25 8:01:22 AM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Haurwitz Rachel E. was granted 136,750 shares, increasing direct ownership by 86% to 295,450 units (SEC Form 4)

      4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

      2/21/25 8:21:07 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Albertson Tina M. was granted 14,589 shares (SEC Form 4)

      4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

      2/21/25 8:20:34 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRBU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Haurwitz Rachel E. bought $20,400 worth of shares (20,000 units at $1.02) (SEC Form 4)

      4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

      3/17/25 8:01:22 AM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Ryali Sriram bought $24,651 worth of shares (17,360 units at $1.42) (SEC Form 4)

      4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

      1/30/25 4:02:12 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRBU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $CRBU
    Financials

    Live finance-specific insights

    See more
    • Caribou Biosciences downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded Caribou Biosciences from Outperform to In-line and set a new price target of $3.00 from $13.00 previously

      6/3/24 7:23:52 AM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Caribou Biosciences

      Cantor Fitzgerald initiated coverage of Caribou Biosciences with a rating of Neutral

      11/8/23 7:19:33 AM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evercore ISI initiated coverage on Caribou Biosciences with a new price target

      Evercore ISI initiated coverage of Caribou Biosciences with a rating of Outperform and set a new price target of $13.00

      10/31/23 8:58:42 AM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

      -- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles) -- -- Plan to enroll ~20 additional 2L LBCL patients in ANTLER to confirm that partial HLA matching improves patient outcomes; initial data expected in H1 2025 -- -- Caribou expects to initiate a pivotal trial for CB-010 in H2 2025, upon confirmation of improved outcomes in partially HLA matched cohort -- -- Off-the-shelf CB-010 is partially HLA matched to patient within current screening timelines -- -- KOL webcast discussion of data from 46

      6/2/24 7:00:00 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

      -- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases -- -- Advancing ANTLER Phase 1 trial for 2L LBCL; initial dose expansion data to be shared at a medical congress in Q2 2024 -- -- Conference call and webcast scheduled for today at 5:00 pm ET -- BERKELEY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, t

      4/4/24 4:00:00 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL

      -- CB-010 allogeneic CAR-T cell therapy data rival response rates and safety profile of approved autologous CAR-T cell therapies -- -- 94% overall response rate (ORR), 69% complete response (CR) rate, and 44% CR rate at ≥6 months following a single dose of CB-010; 24 months is the longest CR maintained to date -- -- LBCL patient subgroup had a 50% CR rate at ≥6 months; 18 months is the longest LBCL subgroup CR maintained to date -- -- Actively enrolling second-line LBCL patients in ANTLER dose expansion -- -- Conference call and webcast scheduled for today at 4:30 pm ET -- BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-s

      7/13/23 4:01:00 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRBU
    Leadership Updates

    Live Leadership Updates

    See more
    • Caribou Biosciences Appoints Sri Ryali as Chief Financial Officer

      BERKELEY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sri Ryali as chief financial officer, effective immediately. Mr. Ryali brings 20 years of finance and commercial experience in the biopharmaceutical industry to his role, and he will be responsible for the strategic leadership of the corporate finance, investor relations, and corporate communications functions. He will report to Rachel Haurwitz, PhD, Caribou's president and chief executive officer. "I am excited to welcome Sri to Caribou at the beginning of this pivotal year for our organiz

      1/2/25 8:00:00 AM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer

      -- Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical development of CAR-T cell therapies -- BERKELEY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Tina Albertson, MD, PhD, as chief medical officer. Dr. Albertson brings 15 years of experience leading clinical drug development of cellular therapies and biologics. She will be responsible for strategic leadership of the clinical, regulatory, and medical affairs functions, and provide medical and operational leadership of Caribou's four clin

      8/12/24 8:00:00 AM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board

      -- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Terri Laufer, MD, to its scientific advisory board. Dr. Laufer is a leading rheumatologist known for her extensive research into immune cell regulation and dysfunction that leads to autoimmune diseases. She is an emeritus associate professor of medicine at the Perelman School of Medicine at the University of Pennsylvania and an attending rheumatologist at the Penn Presbyterian Med

      7/9/24 8:00:00 AM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care